Monitoring cellular immune responses to cancer immunotherapy.
Many clinical trials are testing the feasibility of stimulating the immune system to treat cancer. Although the efficacy of this approach will ultimately be determined by clinically relevant endpoints, detection of the magnitude and activity of the immune response is an important intermediate point in the development of these strategies. Assays that predict clinically relevant endpoints are particularly desirable for helping to determine which strategies should ultimately be tested in larger randomized clinical trials. In this review, we will discuss these cellular immunological assays and the current status of their role in clinical trials of immunotherapy.
Morse
M A
MA
Duke University Medical Center, Box 3233, Durham, NC 27710, USA. m.morse@cgct.duke.edu
Clay
T M
TM
Hobeika
A C
AC
Mosca
P J
PJ
Lyerly
H K
HK
D000818:Animals; D002986:Clinical Trials as Topic; D022801:Complementarity Determining Regions; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D006801:Humans; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D007118:Immunoassay / Q000379:methods*; D007167:Immunotherapy; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D010455:Peptides / Q000276:immunology; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics; D013601:T-Lymphocytes / Q000276:immunology
D022801:Complementarity Determining Regions; D016207:Cytokines; D010455:Peptides; D016693:Receptors, Antigen, T-Cell, alpha-beta